News Sentiment

PHAR sentiment intelligence

Pharming Group NV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.86 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+0.7% over one week, +8.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Pharming Group to report Q2 and H1 2026 results on July 30

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction 0.7% Price digesting
Trend fit Trend inactive 8.2% over four weeks
Fair value 18.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Market source 6
GlobeNewswire 6
Stock Traders Daily 3
Quartr 2
TradingKey 2
MT Newswires 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Earnings 21
Market update 19
Analyst action 3
Deals and strategy 2
Regulatory and legal 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
scanx.trade Direct company coverage

Pharming Group to report Q2 and H1 2026 results on July 30

Pharming Group N.V. will release its Q2 and H1 2026 preliminary financial results on July 30, 2026, including a business update. A conference call and webcast for analysts and investors are scheduled for the same day at 13:30 CEST. Participants must register in advance to join th

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 06:41
Source
scanx.trade
GlobeNewswire Direct company coverage

Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

Pharming Group N.V. announced that it will report its unaudited financial results for the second quarter and first half of 2026 on Thursday, July 30, 2026. The company will also provide a business update and host a conference call and webcast for analysts and investors on the sam

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 05:41
Source
GlobeNewswire
Quartr Direct company coverage

Pharming Group (PHARM) M&A Announcement Summary

Pharming Group announced the acquisition of Abliva AB for approximately $66.1 million through a public tender offer. This strategic move aims to expand Pharming's rare disease pipeline with Abliva's lead asset, KL1333, a first-in-class therapy for primary mitochondrial disease wi

Tone
Positive 73/100
Event
Deals and strategy
Published
15 Jul 2026 22:41
Source
Quartr
TradingView Direct company coverage

XS276301888 Bond Profile — Key Metrics

This article provides a detailed profile of the XS276301888 bond issued by Pharming Group N.V. Key metrics such as the 4.50% coupon, April 25, 2029, maturity date, and an outstanding amount of EUR 100 million are highlighted. The bond's face value and minimum denomination are bot

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 19:41
Source
TradingView
TradingView Direct company coverage

XS276301888 Bond Coupon Profile — Rate & Payments

This article provides the coupon profile for the Pharming Group N.V. bond XS276301888, highlighting its current coupon rate of 4.50%. It indicates that the next interest payment is scheduled for October 26, 2026. The page offers an overview of the bond's interest payment details,

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 06:40
Source
TradingView
PR Newswire UK Direct company coverage

Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS

Pharming Group N.V. has received US FDA approval for Joenja® (leniolisib), making it the first and only approved treatment for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients aged 12 and older. Joenja®, an oral PI3Kδ inhibitor, is

Tone
Positive 90/100
Event
Regulatory and legal
Published
12 Jul 2026 21:39
Source
PR Newswire UK
Stock Titan Direct company coverage

If You Invested $1,000 in Pharming Group N.V. (PHAR)

This article analyzes the historical performance of an investment in Pharming Group N.V. (PHAR), a global biopharmaceutical company focusing on rare diseases. It details how a $1,000 investment would have performed over one and five years, indicating positive returns but no 10-ye

Tone
Positive 64/100
Event
Market update
Published
12 Jul 2026 02:11
Source
Stock Titan
Stock Traders Daily Direct company coverage

Understanding the Setup: (PHAR) and Scalable Risk

This article analyzes Pharming Group N.v. (NASDAQ: PHAR), highlighting a near-term neutral sentiment amidst mid and long-term strength. It identifies a significant 69.0:1 risk-reward setup targeting a 21.3% gain with minimal risk, and outlines institutional trading strategies, in

Tone
Positive 72/100
Event
Market update
Published
11 Jul 2026 20:11
Source
Stock Traders Daily
Quartr Direct company coverage

Pharming Group (PHARM) Q1 2025 earnings summary

Pharming Group reported strong Q1 2025 revenues of $79.1 million, a 42% year-over-year increase, driven by significant growth in RUCONEST® and Joenja® sales. The company completed the acquisition of Abliva, expanding its pipeline, and raised its 2025 revenue guidance to $325–340

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 08:09
Source
Quartr
TradingView Direct company coverage

Price to book forward of Pharming Group NV – EURONEXT:PHARM

This article provides the "Price to book forward" financial metric for Pharming Group NV (EURONEXT:PHARM). The content displays a table with period, value, change, and change percentage, specifically stating "No trades" and "Market closed." It appears to be a financial data snipp

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 03:10
Source
TradingView
Investing.com Direct company coverage

Pharming Q1 2026 slides: Joenja growth offset by RUCONEST decline

Pharming Group N.V. reported an 8% revenue decline in Q1 2026, leading to a 22.15% stock price drop, primarily due to competitive pressures on its RUCONEST product. Despite this, the company saw substantial growth in its Joenja franchise and reaffirmed its full-year 2026 revenue

Tone
Negative 38/100
Event
Earnings
Published
06 Jul 2026 06:40
Source
Investing.com
Simply Wall Street Direct company coverage

High Growth Tech Stocks In Europe Featuring 3 Promising Picks

This article identifies three promising high-growth tech stocks in Europe: Pharming Group, Acast, and Dustin Group. It highlights their recent developments, financial performance, and growth prospects within the context of a resilient European market. The piece offers a brief ove

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 05:43
Source
Simply Wall Street
TradingView Direct company coverage

Pharming Group N.V. Stock 12‑Month Price Target Raised to $32.69, Implies 137% Upside

Analysts have raised the 12-monthprice target for Pharming Group N.V. (PHARM) stock to $32.69 from $31.09, based on estimates from 5 analysts. This new target implies a potential upside of approximately 137% from the July 2nd closing price. The consensus rating for the stock rema

Tone
Positive 75/100
Event
Analyst action
Published
04 Jul 2026 22:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Pharming Group NV – EURONEXT:PHARM

The article provides financial data on Pharming Group NV (EURONEXT:PHARM), specifically highlighting its enterprise value to EBIT forward. It appears to be a financial data snippet from TradingView, offering an overview of the company's financial metrics. The content is concise a

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 07:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Pharming Group NV – EURONEXT:PHARM

This article provides a brief overview of Pharming Group NV (EURONEXT:PHARM) on TradingView, focusing on its financial metrics, specifically the price to sales forward. It does not offer any specific financial figures or analysis but highlights the company's presence on the platf

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 00:39
Source
TradingView
Stock Traders Daily Direct company coverage

The Technical Signals Behind (PHAR) That Institutions Follow

This article analyzes Pharming Group N.v. (NASDAQ: PHAR) based on AI-generated technical signals. It highlights strong sentiment across all horizons, an exceptional risk-reward setup targeting a 21.2% gain, and outlines three distinct trading strategies (Position, Momentum Breako

Tone
Positive 77/100
Event
Market update
Published
30 Jun 2026 19:06
Source
Stock Traders Daily
The National Law Review Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V. (PHAR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pharming Group N.V. (NASDAQ: PHAR) securities. This investigation follows a significant stock price drop after the FDA issued a Complete Response Letter to Pharming's sNDA for Joenja®,

Tone
Negative 14/100
Event
Regulatory and legal
Published
30 Jun 2026 12:39
Source
The National Law Review
TradingView Direct company coverage

A2QLQY Forecast — Price Target — Prediction for 2027

This article provides a price target and forecast for Pharming Group NV Sponsored ADR (A2QLQY) for 2027, based on analysis from 6 analysts. It states a price target of 26.85 and includes sections for annual and quarterly EPS and revenue metrics. The content also contains a discla

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 11:41
Source
TradingView
TradingView Direct company coverage

Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR)

This article provides access to the financial actuals and estimates for Pharming Group N.V. (NASDAQ: PHAR) on TradingView. It allows users to explore reported financial data and analyst estimates, comparing actual results with various estimates and visualizing trends over time ac

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 11:39
Source
TradingView
TradingView Direct company coverage

PHG Forecast — Price Target — Prediction for 2027

This article provides the 1-year price target forecast for Pharming Group NV Sponsored ADR (PHG) based on input from 6 analysts. It states a price target of 26.85 but notes that maximum and minimum estimates were not provided. The article also touches on analyst ratings, EPS, and

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 10:39
Source
TradingView
Market source Direct company coverage

Pharming Group (ENXTAM:PHARM) Stock Gets Fair Value Boost As Joenja Progress Supports Growth Case

Pharming Group's fair value estimate has been raised from €2.11 to €2.36 by analysts, driven by adjusted revenue growth assumptions and revised future P/E multiples. This update reflects a balance of optimism regarding the company's growth potential, particularly with its Joenja

Tone
Positive 65/100
Event
Earnings
Published
27 Jun 2026 09:08
Source
Market source
TradingView Direct company coverage

Pharming Group NV Actuals & Estimates (EURONEXT:PHARM)

This article provides an overview of Pharming Group NV (EURONEXT:PHARM) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers various metrics such as market capitalization, volatility, earnings, revenue, and EBITDA, while als

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 15:41
Source
TradingView
TradingView Direct company coverage

Pharming Group NV Actuals & Estimates (AQUISUK:PHARMA)

This article provides details on Pharming Group NV (PHARMA) stock, including financial actuals and estimates. It covers analyst price targets with a range of 1.80 EUR to 3.45 EUR, historical price data, upcoming earnings dates, and past financial performance such as revenue, net

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 19:11
Source
TradingView
TradingKey Direct company coverage

Pharming Group NV (PHAR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Pharming Group NV (PHAR), focusing on indicators and moving averages to assess its stock performance. It details various technical indicators like MACD, RSI, and STOCH, along with an analysis of moving averages (MA5 to MA200), conclud

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 01:40
Source
TradingKey
Stock Traders Daily Direct company coverage

Precision Trading with Pharming Group N.v. (PHAR) Risk Zones

The article provides a detailed analysis of Pharming Group N.v. (PHAR) stock, highlighting positive near-term sentiment within a long-term strength context despite elevated downside risk due to a lack of additional long-term support signals. It outlines three AI-generated institu

Tone
Positive 69/100
Event
Market update
Published
20 Jun 2026 01:10
Source
Stock Traders Daily
TradingKey Direct company coverage

Pharming Group NV (PHAR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Pharming Group NV (PHAR), indicating a "Strong Buy" analyst rating based on 6 analysts. It highlights that relevant financial forecasting data for EPS, Revenue, and Net Profit has not yet been disclosed by the company. The article al

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 04:40
Source
TradingKey